- Risk of Diabetic Retinopathy between Sodium-Glucose Cotransporter-2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists
-
Lin TY, Kang EYC, Shao SC, Lai ECC, Garg SJ, Chen KJ, Kang JH, Wu WC, Lai CC, Hwang YS
- KMID: 2542516
- Diabetes Metab J.
- 2023 May;47(3):394-404.
- doi: 10.4093/dmj.2022.0221
Background: To compare risk of diabetic retinopathy (DR) between patients taking sodium-glucose cotransporter-2 inhibitors (SGLT2is) and those taking glucagon-like peptide-1 receptor agonists (GLP1-RAs) in routine care. Methods: This retrospective cohort study... -
- CITED
-
- Close
- SHARE
-
- Close
